Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

UPDATE 1-Australia's Sigma Healthcare loses pharma contract to NZ's EBOS

Published 02/07/2018, 11:30 am
Updated 02/07/2018, 11:40 am
© Reuters.  UPDATE 1-Australia's Sigma Healthcare loses pharma contract to NZ's EBOS
SIG
-

(Adds details on rival EBOS Group's contract win, share performance)

July 2 (Reuters) - Australian pharmacy operator Sigma Healthcare Ltd SIG.AX lost nearly half of its value on Monday after it failed to extend a supply contract with Chemist Warehouse, a pharmacy operator which dominates the "daigou" or Chinese buying agent market.

The loss of the contract forced Sigma to lower its fiscal 2018 underlying operating earnings guidance to about A$75 million ($55.5 million) from an earlier A$90 million, and to roughly halve it to a range of A$40-50 million in fiscal 2020.

Sigma shares fell more than 45 percent to their worst level in nearly seven years in morning trade, while the broader market was 0.3 percent higher.

Meanwhile, New Zealand's EBOS Group Ltd EBO.NZ soared to a record high after it snapped up the deal to distribute pharmaceutical products to over 400 Chemist Warehouse and My Chemist stores in Australia.

EBOS estimated sales from the contract would add about A$1 billion to revenue in the first year after the agreement.

Sigma would continue to supply Chemist Warehouse and My Chemist Group under existing terms till June 30, 2019, the company said in a statement.

EBOS said it expected to enter a five-year supply deal, effective from July 1, 2019. ($1 = 1.3524 Australian dollars)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.